[go: up one dir, main page]

DE60317690D1 - Verfahren zur herstellung von valsartan - Google Patents

Verfahren zur herstellung von valsartan

Info

Publication number
DE60317690D1
DE60317690D1 DE60317690T DE60317690T DE60317690D1 DE 60317690 D1 DE60317690 D1 DE 60317690D1 DE 60317690 T DE60317690 T DE 60317690T DE 60317690 T DE60317690 T DE 60317690T DE 60317690 D1 DE60317690 D1 DE 60317690D1
Authority
DE
Germany
Prior art keywords
preparing valsartan
valsartan
preparing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60317690T
Other languages
English (en)
Other versions
DE60317690T2 (de
Inventor
Donatienne Denni-Dischert
Hans Hirt
Dan Neville
Gottfried Sedelmeier
Anita Schnyder
Nadine Derrien
Daniel Kaufmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9944606&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60317690(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Publication of DE60317690D1 publication Critical patent/DE60317690D1/de
Application granted granted Critical
Publication of DE60317690T2 publication Critical patent/DE60317690T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D257/00Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04Five-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
DE60317690T 2002-09-23 2003-09-22 Verfahren zur herstellung von valsartan Expired - Lifetime DE60317690T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0222056.4A GB0222056D0 (en) 2002-09-23 2002-09-23 Process for the manufacture of organic compounds
GB0222056 2002-09-23
PCT/EP2003/010543 WO2004026847A1 (en) 2002-09-23 2003-09-22 Process for the manufacture of valsartan

Publications (2)

Publication Number Publication Date
DE60317690D1 true DE60317690D1 (de) 2008-01-03
DE60317690T2 DE60317690T2 (de) 2008-10-30

Family

ID=9944606

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60317690T Expired - Lifetime DE60317690T2 (de) 2002-09-23 2003-09-22 Verfahren zur herstellung von valsartan

Country Status (30)

Country Link
US (3) US20060069268A1 (de)
EP (2) EP1878729A1 (de)
JP (2) JP4787498B2 (de)
KR (2) KR20110015703A (de)
CN (2) CN100357279C (de)
AR (1) AR041360A1 (de)
AU (1) AU2003270241B2 (de)
BR (1) BR0314132A (de)
CA (1) CA2502629A1 (de)
CY (1) CY1107878T1 (de)
DE (1) DE60317690T2 (de)
DK (1) DK1546122T3 (de)
EC (2) ECSP055695A (de)
ES (1) ES2295623T3 (de)
GB (1) GB0222056D0 (de)
HK (1) HK1079771A1 (de)
IL (1) IL167426A (de)
MX (1) MXPA05003140A (de)
MY (1) MY138618A (de)
NO (2) NO20051970L (de)
NZ (2) NZ538927A (de)
PE (2) PE20050088A1 (de)
PL (1) PL374862A1 (de)
PT (1) PT1546122E (de)
RU (2) RU2348619C2 (de)
SG (1) SG155049A1 (de)
SI (1) SI1546122T1 (de)
TW (2) TWI338003B (de)
WO (1) WO2004026847A1 (de)
ZA (1) ZA200502159B (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7199144B2 (en) 2003-04-21 2007-04-03 Teva Pharmaceuticals Industries, Ltd. Process for the preparation of valsartan and intermediates thereof
EP1511739B1 (de) * 2003-03-17 2008-04-30 Teva Pharmaceutical Industries Ltd. Polymorphe formen von valsartan
US7378531B2 (en) 2003-04-21 2008-05-27 Teva Pharmaceutical Industries Ltd Process for the preparation of valsartan
EP1556363A2 (de) * 2003-04-21 2005-07-27 Teva Pharmaceutical Industries Limited Verfahren zur herstellung von valsartan und zwischenprodukte davon
GB0316546D0 (en) 2003-07-15 2003-08-20 Novartis Ag Process for the manufacture of organic compounds
GB0402262D0 (en) * 2004-02-02 2004-03-10 Novartis Ag Process for the manufacture of organic compounds
EP1661891A1 (de) * 2004-11-30 2006-05-31 KRKA, D.D., Novo Mesto Verfahren zur Herstellung von Valsartan
GB0514206D0 (en) 2005-07-11 2005-08-17 Novartis Ag Organic compounds
ES2288376B1 (es) * 2005-10-20 2008-11-01 Inke, S.A. Procedimiento para la obtencion de intermedios utiles en la obtencion de un compuesto farmaceuticamente activo.
WO2007057919A2 (en) * 2005-10-25 2007-05-24 Alembic Limited An improved process for preparation of (s)-n-(1-carboxy-2-methyl-prop-1-yl)-n-pentanoyl-n-[2'-(1h-tetrazol-5-yl)biphenyl-4-ylmethyl]-amine
EP2057132A2 (de) * 2006-07-03 2009-05-13 Aurobindo Pharma Limited Verfahren zur herstellung des angiotensin-ii-antagonisten valsartan
ES2315141B1 (es) * 2006-11-23 2009-12-22 Quimica Sintetica, S.A Procedimiento para la preparacion de cardesartan cilexetilo en forma cristalina.
CN101200455B (zh) * 2007-09-29 2010-08-18 泰兴市江神化工有限公司 沙坦类治疗高血压药物主环5-(4'-甲酰基联苯-2-基)-1h-四氮唑的制备方法
US7943794B2 (en) * 2008-02-13 2011-05-17 Ranbaxy Laboratories Limited Processes for the preparation of intermediates of valsartan
KR101012135B1 (ko) * 2008-12-18 2011-02-07 주식회사 대희화학 발사르탄 메틸 에스테르의 제조방법
EP2316821A1 (de) 2009-10-27 2011-05-04 Novartis AG Verfahren zur Herstellung organischer Verbindungen
SG187007A1 (en) * 2010-08-03 2013-02-28 Novartis Ag Highly crystalline valsartan
CN102351804B (zh) * 2011-09-30 2013-07-31 浙江新赛科药业有限公司 一种缬沙坦消旋体的回收方法
CN103554047A (zh) * 2013-10-11 2014-02-05 镇江市高等专科学校 制备缬沙坦的方法
CN103923028B (zh) * 2014-05-04 2017-05-24 青岛雪洁助剂有限公司 一种缬沙坦甲酯的制备方法
CN104072433A (zh) * 2014-07-16 2014-10-01 南京正大天晴制药有限公司 一种缬沙坦的水解杂质化合物及其制备方法、检测方法和用途
CN104151199A (zh) * 2014-08-13 2014-11-19 苏州卫生职业技术学院 一种缬沙坦的合成方法
CN104844476B (zh) * 2015-04-03 2016-08-24 李凌 一种医药中间体联苯类化合物的合成方法
CN112014479A (zh) * 2019-05-28 2020-12-01 珠海润都制药股份有限公司 一种缬沙坦中正戊酰氯的检测方法
CN116655498B (zh) * 2023-05-24 2025-01-28 江苏阿尔法集团福瑞药业(宿迁)有限公司 一种沙库巴曲中间体的制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2084801T3 (es) * 1990-02-19 1996-05-16 Ciba Geigy Ag Acil compuestos.
US5260325A (en) * 1991-08-19 1993-11-09 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking tertiary amides
FR2688503B1 (fr) * 1992-03-16 1994-05-06 Synthelabo Procede de preparation de derives de 2-(tetrazol-5-yl)-[1,1'-biphenyle].
EP0550313A1 (de) * 1991-12-30 1993-07-07 Synthelabo 2-(Tetranol-5-yl)-(1,1'-Biphenyl)derivate, ihre Herstellung und Anwendung als Zwischenverbindungen
US5284957A (en) * 1992-09-03 1994-02-08 Eli Lilly And Company Excitatory amino acid receptor antagonists
JPH08165292A (ja) * 1993-10-07 1996-06-25 Techno Res Kk アデニン誘導体、その製造法及び用途
US5412102A (en) * 1994-05-27 1995-05-02 Syntex (U.S.A.) Inc. Processes for preparing 1-butyl-2-[2'-(2H-tetrazol-5-yl) biphenyl-4-ylmethyl]-1H-indole-3-carboxylic acid
US5468867A (en) * 1994-05-27 1995-11-21 Syntex (U.S.A.) Inc. Process for preparing1-butyl-2-[2'-(2H-tetrazol-5-yl)biphenyl-4-ylmethyl1-1H-indole-3-carboxylic acid
WO1996009301A1 (fr) * 1994-09-20 1996-03-28 Wakunaga Seiyaku Kabushiki Kaisha Procede de production d'un derive de n-biphenylmethylthiadiazoline ou un sel de celui-ci et son intermediaire de production
HUP9900871A3 (en) * 1995-06-07 2000-07-28 Wyeth Corp Process for preparation of biphenyl derivatives
CN1137887C (zh) * 2000-04-07 2004-02-11 常州四药制药有限公司 一种合成缬沙坦的改进方法
ES2309090T3 (es) * 2000-07-19 2008-12-16 Novartis Ag Sales de valsartan.
GB0402262D0 (en) * 2004-02-02 2004-03-10 Novartis Ag Process for the manufacture of organic compounds

Also Published As

Publication number Publication date
CA2502629A1 (en) 2004-04-01
MY138618A (en) 2009-07-31
RU2008133680A (ru) 2010-02-27
US20090111995A1 (en) 2009-04-30
TWI329106B (en) 2010-08-21
TW201016673A (en) 2010-05-01
NO20110856L (no) 2005-06-16
AU2003270241B2 (en) 2007-08-23
BR0314132A (pt) 2005-06-28
SG155049A1 (en) 2009-09-30
JP2006502178A (ja) 2006-01-19
TWI338003B (en) 2011-03-01
PE20050088A1 (es) 2005-02-21
CN1688556A (zh) 2005-10-26
CY1107878T1 (el) 2013-06-19
IL167426A (en) 2010-11-30
US20060069268A1 (en) 2006-03-30
ES2295623T3 (es) 2008-04-16
EP1546122A1 (de) 2005-06-29
ECSP105695A (es) 2010-03-31
DK1546122T3 (da) 2008-03-03
PE20091387A1 (es) 2009-10-13
KR20050057529A (ko) 2005-06-16
AR041360A1 (es) 2005-05-11
CN100357279C (zh) 2007-12-26
TW200413337A (en) 2004-08-01
US20100249429A1 (en) 2010-09-30
AU2003270241A1 (en) 2004-04-08
DE60317690T2 (de) 2008-10-30
JP2010254709A (ja) 2010-11-11
CN101153027B (zh) 2010-08-18
NO20051970L (no) 2005-06-16
KR20110015703A (ko) 2011-02-16
NZ566863A (en) 2009-08-28
PL374862A1 (en) 2005-11-14
RU2005112444A (ru) 2006-01-20
WO2004026847A1 (en) 2004-04-01
EP1546122B1 (de) 2007-11-21
EP1546122B8 (de) 2008-05-28
ZA200502159B (en) 2005-09-21
PT1546122E (pt) 2008-02-14
NZ538927A (en) 2008-05-30
SI1546122T1 (sl) 2008-04-30
MXPA05003140A (es) 2005-06-22
ECSP055695A (es) 2005-05-30
CN101153027A (zh) 2008-04-02
GB0222056D0 (en) 2002-10-30
RU2348619C2 (ru) 2009-03-10
RU2412173C2 (ru) 2011-02-20
JP4787498B2 (ja) 2011-10-05
HK1079771A1 (en) 2006-04-13
EP1878729A1 (de) 2008-01-16

Similar Documents

Publication Publication Date Title
DE502004009768D1 (de) Verfahren zur herstellung von dreiwertigen organophosphor-verbindungen
DE60317690D1 (de) Verfahren zur herstellung von valsartan
DE60323192D1 (de) Verfahren zur Herstellung von Hydroxyalkylstärkederivaten
DE502004009763D1 (de) Verfahren zur herstellung von 1-buten
DE50307672D1 (de) Verfahren zur herstellung von polycarbonaten
DE602004010234D1 (de) Verfahren zur herstellung von 4-aminodiphenylamin
ATE515500T1 (de) Verfahren zur herstellung von telmisartan
DE60328522D1 (de) Verfahren zur herstellung von bisphenol
DE60302139D1 (de) Verfahren zur herstellung von aripiprazole
DE50311721D1 (de) Verfahren zur Herstellung von Aryl-aminopropanolen
ATE553103T1 (de) Verfahren zur herstellung von (s)-pantoprazol
DE50303611D1 (de) Verfahren zur herstellung von polyisobuten
DE60322356D1 (de) Verfahren zur herstellung von 2-aminoindanderivaten
DE502004004318D1 (de) Verfahren zur herstellung von metall-matrix-verbundwerkstoffen
DE602004004677D1 (de) Verfahren zur herstellung substituierter 5-amino-pyrazolo-ä4,3-eü-1,2,4-triazoloä1,5-cüpyrimidine
DE60335766D1 (de) Verfahren zur Herstellung von m-Xylylendiamin
DE502004002810D1 (de) Verfahren zur herstellung von copolymerisaten
DE602004005239D1 (de) Verfahren zur herstellung von tubulininhibitoren
DE602004027840D1 (de) Verfahren zur herstellung von thiazolopyrimidinen
DE60314113D1 (de) Verfahren zur herstellung von phenylorganosiliciumzwischenprodukten
DE60301444T2 (de) Verfahren zur Herstellung von Polyalkylphenoxyaminoalkanen
DE602004018447D1 (de) Verfahren zur Herstellung von Alkylbenzaldehyden
DE602004031740D1 (de) Verfahren zur herstellung von konzentraten
DE60324881D1 (de) Verfahren zur Herstellung von Polyalkylphenoxyaminoalkanen
DE60330749D1 (de) Verfahren zur herstellung von 7-alpha-methylsteroide

Legal Events

Date Code Title Description
8363 Opposition against the patent
8328 Change in the person/name/address of the agent

Representative=s name: KROHER, STROBEL RECHTS- UND PATENTANWAELTE, 80336

8328 Change in the person/name/address of the agent

Representative=s name: DR. SCHOEN & PARTNER, 80336 MUENCHEN